Top Stories

Covaxin Booster Dose: Covaxin booster 90% effective against Omicron, says study | Hyderabad News

HYDERABAD: A booster shot of indigenously developed vaccine, Covaxin, after two doses is able to generate robust antibody responses and neutralise the Omicron (B. 1. 529) and Delta (B. 1. 617. 2) variants of SARS-CoV-2, a study conducted by Atlantabased Emory University has found.
In the study, conducted by the Emory Vaccine Centre using a live virus neutralisation assay, 100% of the test serum samples showed neutralization of the Delta variant and more than 90% of serum samples showed neutralization of the Omicron variant, Bharat Biotech said on Wednesday.
As part of the study, which is set to be published on preprint server medRxiv soon, blood serum collected from13 participants of Covaxin’s Phase-2 clinical trials (conducted in 2020) 28 days after they received their third shot (in 2021) was analysed for the neutralising response against the two variants.
All the participants had received the first two doses, 28 days apart and the third dose six months after the second dose. The study was sponsored by Bharat Biotech’s partner for US & Canada, Ocugen Inc.
Company has achieved its goal of making global vax: Ella
Bharat Biotech said the study showed that neutralization activity of Covaxin-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant, with more than 90% of all individuals boosted with Covaxin showing neutralising antibodies.
“Data from this preliminary analysis show individuals receiving a booster dose of Covaxin have a significant immune response to both the Omicron and Delta variants. These findings suggest that a booster dose has the potential to reduce disease severity and hospitalizations,” said Mehul Suthar, assistant professor of the Emory Vaccine Center at Emory University, who led lab analysis.
“The positive neutralization responses against the Omicron and Delta variants, validates our hypothesis of a multiepitope vaccine generating both humoral and cell mediated immune responses,” said Bharat Biotech chairman & managing director Dr Krishna Ella, adding that with Covaxin, the company has achieved its goal of developing a global universal vaccine for adults and children.
According to Dr Shankar Musunuri, chairman, CEO & co-founder of Ocugen Inc, this encouraging data demonstrates value of Covaxin as a primary and booster vaccine. “These results show how a broad-spectrum vaccine has the potential ability to address ever-shifting public health challenges such as new variants,” said Dr Musunuri.

Source link

Show More

Related Articles

Back to top button